ArticleTranslational andrology and urology2025
Integration of genetic, proteomic, and transcriptomic data identifies therapeutic targets and prognostic biomarkers in bladder cancer.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BC) is a prevalent urinary tract malignancy with high morbidity and mortality. Despite advances in therapeutic modalities, early diagnosis and precise treatment remain challenging, highlighting the need for reliable biomarkers and therapeutic targets. This study aims to identify molecular targets and drug candidates for BC by integrating cross-omics quantitative trait loci (xQTLs), OLINK proteomics (a high-throughput plasma protein measurement platform), and transcriptomics data, alongside prospective cohort studies and multi-omics analyses. Methods: We utilized data from the UK Biobank Pharma Proteomics Project (UKB-PPP), deCODE Genetics, and the Atherosclerosis Risk in Communities study (ARIC). Protein quantitative trait loci (pQTLs) associated with BC were screened via Summary-data-based Mendelian Randomization (SMR). Associations between proteins and BC risk were evaluated using Cox regression and a random survival forest (RSF) model. Drug targets were identified through genome-wide association studies (GWAS) and co-localization, while expression quantitative trait loci (eQTLs) analyses and single-cell RNA sequencing investigated gene expression and cellular heterogeneity. Methylation quantitative trait loci (mQTLs) analysis provided insights into epigenetic mechanisms. Results: Among the 16 proteins associated with BC, seven exhibited a positive correlation: MFGE8, ROR1, CTSS, CLEC4G, PLAT, CD59, TNFRSF19. The RSF model demonstrated superior performance. Co-localization analyses identified WFDC1, GSTM4, and RHOC as potential drug targets. Molecular docking validated camptothecin and lycorine as promising therapeutic candidates. eQTLs analyses implicated MFGE8, CTSS, TNFRSF19, and IL1RAP in BC risk and prognosis. Methylation analyses indicated complex regulation of CTSS and TNFRSF19. Conclusions: WFDC1, RHOC, and GSTM4 exhibit therapeutic potential, while MFGE8, CTSS, TNFRSF19, and IL1RAP predict risk and prognosis, providing insights for precision diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.